Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > 2.39 ASK

<< Previous

Bullboard Posts

Next >>

Comment by Bertie20on Oct 14, 2021 4:29pm

111 Views

Post# 34006852

RE:RE:RE:RE:RE:RE:RE:RE:RE:2.39 ASK

Thanks GoldenArm! I saw your recommendation for Arch on the DME board, checked it out, and went with it. So many thanks for the heads up!

The way Arch is going, I can see its share price surpassing DME's quite soon. I love the risk:reward potential on this one, but it's pretty tense waiting for these peer-reviewed phase II results. It's alot like waiting for the result of a helium exploration well!

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading